“in PCW, we’ve made some provision for the softening consumer demand to persist into next year, as well as potentially more decline in COVID for next year - we have factored that into our guidance”

In context

“cy services that we’re experiencing in 2023 will pull through favorably into our 2024 performance. I would note that not all this favorability will pull through as it will naturally work its way into client pricing as contracts reset in 2024, so you can see the magnitude of our increase for this year, it’s obviously not that much because we’re not going to pull all that through, but it’s a meaningful positive item for next year. Similarly, I think on the headwind side, the largest provision we’ve made in our guidance has to do with the Medicare Advantage performance. We’ve sort of sized the impact of that for this year and have made provision for potential headwind on that, so I think you can kind of get in the neighborhood there, that would be the biggest other one. Then the other one is in PCW, we’ve made some provision for the softening consumer demand to persist into next year, as well as potentially more decline in COVID for next year - we have factored that into our guidance, and as I was mentioning on the previous question, we’ve built in the full effect of the Oak Street acceleration as well. Obviously that’s a choice we’re making in an investment in the future. Karen Lynch: Nathan, just to comment, I want to be very clear that we took a very thoughtful and careful approach to this restructuring. We were very deliberate in making sure that we had non-customer facing roles and that we weren’t taking any action that would risk the execution of our long term strategy. Shawn Guertin: Yes, and just one housekeeping thing in that, again as always, we’re removed the PYD that’s close to a nickel, probably, where we are on a year-to-date basis, and so we’ve taken that out as well for 2024. Operator: Our next question comes from Josh Raskin from Nephron Research. Jo”